BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Yearly Reports

Annual Report 2020

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Corporate Presentation

Arctic Securities Biotech Webinar 2021

22 April 2021

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BERGENBIO ASA: Minutes from the Annual General Meeting

BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)

BERGENBIO CLOSES RECRUITMENT INTO TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS

More News

Scientific Presentations

CROI 2021, Wendy Maury et al.

Read More

Annual Report 2020

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

14th Annual European Life Sciences (SACHS) CEO Forum

H.C. Wainwright Global Life Sciences Conference

Carnegie Healthcare Seminar 2021

BERGENBIO ASA: ANNUAL GENERAL MEETING

BERGENBIO ASA: Invitation to FOURTH quarter 2020 results

More Events

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.